{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T23:59:53Z","timestamp":1790812793704,"version":"4.1.0"},"reference-count":81,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,1,31]],"date-time":"2019-01-31T00:00:00Z","timestamp":1548892800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2019,1,31]],"date-time":"2019-01-31T00:00:00Z","timestamp":1548892800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>A growing body of evidence suggests a key role of tumor microenvironment, especially for bone marrow mesenchymal stem cells (MSC), in the maintenance and progression of multiple myeloma (MM), through direct and indirect interactions with tumor plasma cells. Thus, this study aimed to investigate the gene expression and functional alterations of MSC from MM patients (MM-MSC) in comparison with their normal counterparts from normal donors (ND-MSC). Gene expression analysis (Affymetrix) was performed in MM-MSC and ND-MSC after <jats:italic>in vitro<\/jats:italic> expansion. To validate these findings, some genes were selected to be evaluated by quantitative real time PCR (RT-qPCR), and also functional <jats:italic>in vitro<\/jats:italic> analyses were performed. We demonstrated that MM-MSC have a distinct gene expression profile than ND-MSC, with 485 differentially expressed genes (DEG) - 280 upregulated and 205 downregulated. Bioinformatics analyses revealed that the main enriched functions among downregulated DEG were related to cell cycle progression, immune response activation and bone metabolism. Four genes were validated by qPCR - <jats:italic>ZNF521<\/jats:italic> and <jats:italic>SEMA3A<\/jats:italic>, which are involved in bone metabolism, and <jats:italic>HLA-DRA<\/jats:italic> and <jats:italic>CHIRL1<\/jats:italic>, which are implicated in the activation of immune response. Taken together, our results suggest that MM-MSC have constitutive abnormalities that remain present even in the absence of tumors cells. The alterations found in cell cycle progression, immune system activation, and osteoblastogenesis suggest, respectively, that MM-MSC are permanently dependent of tumor cells, might contribute to immune evasion and play an essential role in bone lesions frequently found in MM patients.<\/jats:p>","DOI":"10.1038\/s41598-018-38314-8","type":"journal-article","created":{"date-parts":[[2019,1,31]],"date-time":"2019-01-31T11:04:33Z","timestamp":1548932673000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":26,"title":["Transcriptome Analysis of Mesenchymal Stem Cells from Multiple Myeloma Patients Reveals Downregulation of Genes Involved in Cell Cycle Progression, Immune Response, and Bone Metabolism"],"prefix":"10.1038","volume":"9","author":[{"given":"Rodrigo Carlini","family":"Fernando","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diego Robles","family":"Mazzotti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hatylas","family":"Azevedo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alex Freire","family":"Sandes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edgar Gil","family":"Rizzatti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariana Bleker","family":"de Oliveira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veruska Lia Fook","family":"Alves","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela Isabel Pereira","family":"Eug\u00eanio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabr\u00edcio","family":"de Carvalho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Aparecida","family":"Dalboni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David Correa","family":"Martins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gisele Wally Braga","family":"Colleoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,1,31]]},"reference":[{"issue":"18","key":"38314_CR1","doi-asserted-by":"publisher","first-page":"1860","DOI":"10.1056\/NEJMra041875","volume":"351","author":"RA Kyle","year":"2004","unstructured":"Kyle, R. A. & Rajkumar, S. V. Multiple myeloma. N. Engl. J. Med. 351(18), 1860\u201373 (2004).","journal-title":"N. Engl. J. Med."},{"issue":"11","key":"38314_CR2","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.1056\/NEJMra1011442","volume":"364","author":"A Palumbo","year":"2011","unstructured":"Palumbo, A. & Anderson, K. Multiple myeloma. N. Engl. J. Med. 364(11), 1046\u201360 (2011).","journal-title":"N. Engl. J. Med."},{"issue":"22","key":"38314_CR3","doi-asserted-by":"publisher","first-page":"5412","DOI":"10.1182\/blood-2008-12-194241","volume":"113","author":"O Landgren","year":"2009","unstructured":"Landgren, O. et al. Monoclonal gammopathy of undetermined significance (MGUS) consistently precedes multiple myeloma: a prospective study. Blood. 113(22), 5412\u20137 (2009).","journal-title":"Blood."},{"issue":"22","key":"38314_CR4","doi-asserted-by":"publisher","first-page":"5418","DOI":"10.1182\/blood-2008-12-195008","volume":"113","author":"BM Weiss","year":"2009","unstructured":"Weiss, B. M., Abadie, J., Verma, P., Howard, R. S. & Kuehl, W. M. A monoclonal gammopathy precedes multiple myeloma in most patients. Blood. 113(22), 5418\u201322 (2009).","journal-title":"Blood."},{"issue":"13","key":"38314_CR5","doi-asserted-by":"publisher","first-page":"1362","DOI":"10.1056\/NEJMoa054494","volume":"354","author":"RA Kyle","year":"2006","unstructured":"Kyle, R. A. et al. Prevalence of monoclonal gammopathy of undetermined significance. N. Engl. J. Med. 354(13), 1362\u20139 (2006).","journal-title":"N. Engl. J. Med."},{"issue":"25","key":"38314_CR6","doi-asserted-by":"publisher","first-page":"2582","DOI":"10.1056\/NEJMoa070389","volume":"356","author":"RA Kyle","year":"2007","unstructured":"Kyle, R. A. et al. Clinical course and prognosis of smoldering (asymptomatic) multiple myeloma. N. Engl. J. Med. 356(25), 2582\u201390 (2007).","journal-title":"N. Engl. J. Med."},{"issue":"5","key":"38314_CR7","doi-asserted-by":"publisher","first-page":"2516","DOI":"10.1182\/blood-2007-10-116129","volume":"111","author":"SK Kumar","year":"2008","unstructured":"Kumar, S. K. et al. Improved survival in multiple myeloma and the impact of novel therapies. Blood. 111(5), 2516\u201320 (2008).","journal-title":"Blood."},{"issue":"5","key":"38314_CR8","doi-asserted-by":"publisher","first-page":"1122","DOI":"10.1038\/leu.2013.313","volume":"28","author":"SK Kumar","year":"2014","unstructured":"Kumar, S. K. et al. Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients. Leukemia. 28(5), 1122\u20138 (2014).","journal-title":"Leukemia."},{"issue":"9","key":"38314_CR9","doi-asserted-by":"publisher","first-page":"1680","DOI":"10.1001\/jama.1969.03160090040009","volume":"208","author":"R Alexanian","year":"1969","unstructured":"Alexanian, R. et al. Treatment for multiple myeloma. Combination chemotherapy with different melphalan dose regimens. Jama. 208(9), 1680\u20135 (1969).","journal-title":"Jama."},{"issue":"8354","key":"38314_CR10","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1016\/S0140-6736(83)90739-0","volume":"2","author":"TJ McElwain","year":"1983","unstructured":"McElwain, T. J. & Powles, R. L. High-dose intravenous melphalan for plasma-cell leukaemia and myeloma. Lancet. 2(8354), 822\u20134 (1983).","journal-title":"Lancet."},{"issue":"21","key":"38314_CR11","doi-asserted-by":"publisher","first-page":"1565","DOI":"10.1056\/NEJM199911183412102","volume":"341","author":"S Singhal","year":"1999","unstructured":"Singhal, S. et al. Antitumor activity of thalidomide in refractory multiple myeloma. N. Engl. J. Med. 341(21), 1565\u201371 (1999).","journal-title":"N. Engl. J. Med."},{"issue":"13","key":"38314_CR12","doi-asserted-by":"publisher","first-page":"4050","DOI":"10.1182\/blood-2005-07-2817","volume":"106","author":"SV Rajkumar","year":"2005","unstructured":"Rajkumar, S. V. et al. Combination therapy with lenalidomide plus dexamethasone (Rev\/Dex) for newly diagnosed myeloma. Blood. 106(13), 4050\u20133 (2005).","journal-title":"Blood."},{"issue":"10","key":"38314_CR13","doi-asserted-by":"publisher","first-page":"3458","DOI":"10.1182\/blood-2006-04-015909","volume":"108","author":"PG Richardson","year":"2006","unstructured":"Richardson, P. G. et al. A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma. Blood. 108(10), 3458\u201364 (2006).","journal-title":"Blood."},{"issue":"30","key":"38314_CR14","doi-asserted-by":"publisher","first-page":"5008","DOI":"10.1200\/JCO.2009.23.6802","volume":"27","author":"M Lacy","year":"2009","unstructured":"Lacy, M. et al. Pomalidomide (CC4047) plus low-dose dexamethasone as therapy for relapsed multiple myeloma. J. Clin. Oncol. 27(30), 5008\u201314 (2009).","journal-title":"J. Clin. Oncol."},{"issue":"22","key":"38314_CR15","doi-asserted-by":"publisher","first-page":"4420","DOI":"10.1200\/JCO.2002.01.133","volume":"20","author":"RZ Orlowski","year":"2002","unstructured":"Orlowski, R. Z. et al. Phase I trial of the proteasome inhibitor PS-341 in patients with refractory hematologic malignancies. J. Clin. Oncol. 20(22), 4420\u20137 (2002).","journal-title":"J. Clin. Oncol."},{"issue":"2","key":"38314_CR16","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1056\/NEJMoa1411321","volume":"372","author":"AK Stewart","year":"2015","unstructured":"Stewart, A. K. et al. Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma. N. Engl. J. Med. 372(2), 142\u201352 (2015).","journal-title":"N. Engl. J. Med."},{"issue":"7","key":"38314_CR17","doi-asserted-by":"publisher","first-page":"1038","DOI":"10.1182\/blood-2014-01-548826","volume":"124","author":"PG Richardson","year":"2014","unstructured":"Richardson, P. G. et al. Phase 1 study of twice-weekly ixazomib, an oral proteasome inhibitor, in relapsed\/refractory multiple myeloma patients. Blood. 124(7), 1038\u201346 (2014).","journal-title":"Blood."},{"issue":"13","key":"38314_CR18","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.1056\/NEJMoa1506348","volume":"373","author":"HM Lokhorst","year":"2015","unstructured":"Lokhorst, H. M. et al. Targeting CD38 with daratumumab monotherapy in multiple myeloma. N. Engl. J. Med. 373(13), 1207\u201319 (2015).","journal-title":"N. Engl. J. Med."},{"issue":"7","key":"38314_CR19","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1056\/NEJMoa1505654","volume":"373","author":"S Lonial","year":"2015","unstructured":"Lonial, S. et al. Elotuzumab therapy for relapsed or refractory multiple myeloma. N. Engl. J. Med. 373(7), 621\u201331 (2015).","journal-title":"N. Engl. J. Med."},{"issue":"8","key":"38314_CR20","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1358\/dot.2015.51.8.2362311","volume":"51","author":"T Cheng","year":"2015","unstructured":"Cheng, T., Grasse, L., Shah, J. & Chandra, J. Panobinostat, a pan-histone deacetylase inhibitor: rationale for and application to treatment of multiple myeloma. Drugs Today (Barc). 51(8), 491\u2013504 (2015).","journal-title":"Drugs Today (Barc)."},{"issue":"20","key":"38314_CR21","doi-asserted-by":"publisher","first-page":"3049","DOI":"10.1182\/blood-2014-11-568881","volume":"125","author":"G Bianchi","year":"2015","unstructured":"Bianchi, G. & Munshi, N. C. Pathogenesis beyond the cancer clone(s) in multiple myeloma. Blood. 125(20), 3049\u201358 (2015).","journal-title":"Blood."},{"issue":"7","key":"38314_CR22","doi-asserted-by":"publisher","first-page":"1667","DOI":"10.3748\/wjg.v20.i7.1667","volume":"20","author":"HW Chung","year":"2014","unstructured":"Chung, H. W. & Lim, J.-B. Role of the tumor microenvironment in the pathogenesis of gastric carcinoma. World J. Gastroenterol. 20(7), 1667\u201380 (2014).","journal-title":"World J. Gastroenterol."},{"issue":"5","key":"38314_CR23","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1007\/s11912-008-0067-y","volume":"10","author":"J Villanueva","year":"2008","unstructured":"Villanueva, J. & Herlyn, M. Melanoma and the tumor microenvironment. Curr. Oncol. Rep. 10(5), 439\u201346 (2008).","journal-title":"Curr. Oncol. Rep."},{"key":"38314_CR24","doi-asserted-by":"publisher","first-page":"1581","DOI":"10.2741\/1642","volume":"10","author":"J Zhou","year":"2005","unstructured":"Zhou, J., Mauerer, K., Farina, L. & Gribben, J. G. The role of the tumor microenvironment in hematological malignancies and implication for therapy. Front Biosci. 10, 1581\u201396 (2005).","journal-title":"Front Biosci."},{"key":"38314_CR25","doi-asserted-by":"publisher","first-page":"1564","DOI":"10.1016\/j.ejca.2005.12.025","volume":"42","author":"CS Mitsiades","year":"2006","unstructured":"Mitsiades, C. S., Mitsiades, N. S., Munshi, N. C., Richardson, P. G. & Anderson, K. C. The role of the bone microenvironment in the pathophysiology and therapeutic management of multiple myeloma: interplay of growth factors, their receptors and stromal interactions. Eur. J. Cancer. 42, 1564\u201373 (2006).","journal-title":"Eur. J. Cancer."},{"issue":"8","key":"38314_CR26","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1038\/nrc2189","volume":"7","author":"T Hideshima","year":"2007","unstructured":"Hideshima, T., Mitsiades, C., Tonon, G., Richardson, P. G. & Anderson, K. C. Understanding multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targets. Nat Rev Cancer. 7(8), 585\u201398 (2007).","journal-title":"Nat Rev Cancer."},{"issue":"4","key":"38314_CR27","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1016\/j.beha.2007.08.002","volume":"20","author":"K Podar","year":"2007","unstructured":"Podar, K., Richardson, P. G., Hideshima, T., Chauhan, D. & Anderson, K. C. The malignant clone and the bone-marrow environment. Best. Pract. Res. Clin. Haematol. 20(4), 597\u2013612 (2007).","journal-title":"Best. Pract. Res. Clin. Haematol."},{"issue":"3","key":"38314_CR28","first-page":"301","volume":"95","author":"J Caers","year":"2008","unstructured":"Caers, J., Van Valckenborgh, E., Menu, E., Van Camp, B. & Vanderkerken, K. Unraveling the biology of multiple myeloma disease: cancer stem cells, acquired intracellular changes and interactions with the surrounding micro-environment. Bull Cancer. 95(3), 301\u201313 (2008).","journal-title":"Bull Cancer."},{"issue":"2","key":"38314_CR29","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1158\/1078-0432.CCR-11-2212","volume":"18","author":"MR Reagan","year":"2012","unstructured":"Reagan, M. R. & Ghobrial, I. M. Multiple myeloma mesenchymal stem cells: characterization, origin, and tumor-promoting effects. Clin. Cancer Res. 18(2), 342\u20139 (2012).","journal-title":"Clin. Cancer Res."},{"issue":"4","key":"38314_CR30","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1016\/j.stem.2008.03.002","volume":"2","author":"P Bianco","year":"2008","unstructured":"Bianco, P., Robey, P. G. & Simmons, P. J. Mesenchymal stem cells: revisiting history, concepts, and assays. Cell Stem Cell. 2(4), 313\u20139 (2008).","journal-title":"Cell Stem Cell."},{"issue":"1","key":"38314_CR31","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1038\/sj.leu.2404466","volume":"21","author":"B Arnulf","year":"2007","unstructured":"Arnulf, B. et al. Phenotypic and functional characterization of bone marrow mesenchymal stem cells derived from patients with multiple myeloma. Leukemia. 21(1), 158\u201363 (2007).","journal-title":"Leukemia."},{"issue":"5","key":"38314_CR32","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1038\/sj.leu.2404621","volume":"21","author":"J Corre","year":"2007","unstructured":"Corre, J. et al. Bone marrow mesenchymal stem cells are abnormal in multiple myeloma. Leukemia. 21(5), 1079\u201388 (2007).","journal-title":"Leukemia."},{"issue":"3","key":"38314_CR33","doi-asserted-by":"publisher","first-page":"e59756","DOI":"10.1371\/journal.pone.0059756","volume":"8","author":"T Andr\u00e9","year":"2013","unstructured":"Andr\u00e9, T. et al. Evidences of early senescence in multiple myeloma bone marrow mesenchymal stromal cells. PLoS One. 8(3), e59756 (2013).","journal-title":"PLoS One."},{"issue":"18","key":"38314_CR34","doi-asserted-by":"publisher","first-page":"8284","DOI":"10.18632\/oncotarget.2058","volume":"5","author":"A Garcia-Gomez","year":"2014","unstructured":"Garcia-Gomez, A. et al. Transcriptomic profile induced in bone marrow mesenchymal stromal cells after interaction with multiple myeloma cells: implications in myeloma progression and myeloma bone disease. Oncotarget. 5(18), 8284\u2013305 (2014).","journal-title":"Oncotarget."},{"issue":"8","key":"38314_CR35","doi-asserted-by":"publisher","first-page":"1515","DOI":"10.1038\/leu.2009.65","volume":"23","author":"M Garayoa","year":"2009","unstructured":"Garayoa, M. et al. Mesenchymal stem cells from multiple myeloma patients display distinct genomic profile as compared with those from normal donors. Leukemia. 23(8), 1515\u201327 (2009).","journal-title":"Leukemia."},{"issue":"2","key":"38314_CR36","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1634\/stemcells.2004-0331","volume":"24","author":"PA Sotiropoulou","year":"2006","unstructured":"Sotiropoulou, P. A., Perez, S. A., Salagianni, M., Baxevanis, C. N. & Papamichail, M. Characterization of the optimal culture conditions for clinical scale production of human mesenchymal stem cells. Stem Cells. 24(2), 462\u201371 (2006).","journal-title":"Stem Cells."},{"issue":"4","key":"38314_CR37","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1080\/14653240600855905","volume":"8","author":"M Dominici","year":"2006","unstructured":"Dominici, M. et al. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy. 8(4), 315\u20137 (2006).","journal-title":"Cytotherapy."},{"key":"38314_CR38","doi-asserted-by":"crossref","unstructured":"Emig D. et al. AltAnalyze and DomainGraph: analyzing and visualizing exon expression data. Nucleic Acids Res. 38(Web Server issue), W755\u201362 (2010).","DOI":"10.1093\/nar\/gkq405"},{"issue":"4","key":"38314_CR39","doi-asserted-by":"publisher","first-page":"e15","DOI":"10.1093\/nar\/gng015","volume":"31","author":"RA Irizarry","year":"2003","unstructured":"Irizarry, R. A. et al. Summaries of Affymetrix GeneChip probe level data. Nucleic Acids Res. 31(4), e15 (2003).","journal-title":"Nucleic Acids Res."},{"issue":"1","key":"38314_CR40","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1111\/j.2517-6161.1995.tb02031.x","volume":"57","author":"Y Benjamini","year":"1995","unstructured":"Benjamini, Y. & Hochberg, Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. Journal of the Royal Statistical Society Series B (Methodological). 57(1), 289\u2013300 (1995).","journal-title":"Journal of the Royal Statistical Society Series B (Methodological)."},{"issue":"11","key":"38314_CR41","doi-asserted-by":"publisher","first-page":"2498","DOI":"10.1101\/gr.1239303","volume":"13","author":"P Shannon","year":"2003","unstructured":"Shannon, P. et al. Cytoscape: a software environment for integrated models of biomolecular interaction networks. Genome Res. 13(11), 2498\u2013504 (2003).","journal-title":"Genome Res."},{"key":"38314_CR42","doi-asserted-by":"crossref","unstructured":"Warde-Farley D. et al. The GeneMANIA prediction server: biological network integration for gene prioritization and predicting gene function. Nucleic Acids Res. 38 (Web Server issue), W214\u201320 (2010).","DOI":"10.1093\/nar\/gkq537"},{"issue":"21","key":"38314_CR43","doi-asserted-by":"publisher","first-page":"2857","DOI":"10.1093\/bioinformatics\/btp517","volume":"25","author":"G Scardoni","year":"2009","unstructured":"Scardoni, G., Petterlini, M. & Laudanna, C. Analyzing biological network parameters with CentiScaPe. Bioinformatics. 25(21), 2857\u20139 (2009).","journal-title":"Bioinformatics."},{"issue":"24","key":"38314_CR44","doi-asserted-by":"publisher","first-page":"3135","DOI":"10.1093\/bioinformatics\/btq596","volume":"26","author":"G Su","year":"2010","unstructured":"Su, G., Kuchinsky, A., Morris, J. H., States, D. J. & Meng, F. GLay: community structure analysis of biological networks. Bioinformatics. 26(24), 3135\u20137 (2010).","journal-title":"Bioinformatics."},{"key":"38314_CR45","doi-asserted-by":"publisher","DOI":"10.1186\/s40246-015-0059-6","volume":"10","author":"H Azevedo","year":"2016","unstructured":"Azevedo, H. et al. Intragraft transcriptional profiling of renal transplant patients with tubular dysfunction reveals mechanisms underlying graft injury and recovery. Hum Genomics. 10, 2 (2016).","journal-title":"Hum Genomics."},{"issue":"1","key":"38314_CR46","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1038\/75556","volume":"25","author":"M Ashburner","year":"2000","unstructured":"Ashburner, M. et al. Gene ontology: tool for the unification of biology. The Gene Ontology Consortium. Nat. Genet. 25(1), 25\u20139 (2000).","journal-title":"Nat. Genet."},{"key":"38314_CR47","doi-asserted-by":"crossref","unstructured":"Gene Ontology Consortium: going forward. Nucleic Acids Res. 43(Database issue), D1049\u201356 (2015).","DOI":"10.1093\/nar\/gku1179"},{"issue":"1","key":"38314_CR48","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1093\/nar\/28.1.27","volume":"28","author":"M Kanehisa","year":"2000","unstructured":"Kanehisa, M. & Goto, S. KEGG: kyoto encyclopedia of genes and genomes. Nucleic Acids Res. 28(1), 27\u201330 (2000).","journal-title":"Nucleic Acids Res."},{"key":"38314_CR49","doi-asserted-by":"crossref","unstructured":"Kanehisa M. et al. Data, information, knowledge and principle: back to metabolism in KEGG. Nucleic Acids Res. 42(Database issue), D199\u2013205 (2014).","DOI":"10.1093\/nar\/gkt1076"},{"issue":"D1","key":"38314_CR50","doi-asserted-by":"publisher","first-page":"D457","DOI":"10.1093\/nar\/gkv1070","volume":"44","author":"M Kanehisa","year":"2016","unstructured":"Kanehisa, M., Sato, Y., Kawashima, M., Furumichi, M. & Tanabe, M. KEGG as a reference resource for gene and protein annotation. Nucleic Acids Res. 44(D1), D457\u201362 (2016).","journal-title":"Nucleic Acids Res."},{"issue":"D1","key":"38314_CR51","doi-asserted-by":"publisher","first-page":"D353","DOI":"10.1093\/nar\/gkw1092","volume":"45","author":"M Kanehisa","year":"2017","unstructured":"Kanehisa, M., Furumichi, M., Tanabe, M., Sato, Y. & Morishima, K. KEGG: new perspectives on genomes, pathways, diseases and drugs. Nucleic Acids Res. 45(D1), D353\u2013d61 (2017).","journal-title":"Nucleic Acids Res."},{"key":"38314_CR52","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2105-14-128","volume":"14","author":"EY Chen","year":"2013","unstructured":"Chen, E. Y. et al. Enrichr: interactive and collaborative HTML5 gene list enrichment analysis tool. BMC Bioinformatics. 14, 128 (2013).","journal-title":"BMC Bioinformatics."},{"issue":"W1","key":"38314_CR53","doi-asserted-by":"publisher","first-page":"W90","DOI":"10.1093\/nar\/gkw377","volume":"44","author":"MV Kuleshov","year":"2016","unstructured":"Kuleshov, M. V. et al. Enrichr: a comprehensive gene set enrichment analysis web server 2016 update. Nucleic Acids Res. 44(W1), W90\u20137 (2016).","journal-title":"Nucleic Acids Res."},{"issue":"1","key":"38314_CR54","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1038\/nprot.2008.211","volume":"4","author":"DW Huang","year":"2009","unstructured":"Huang, D. W., Sherman, B. T. & Lempicki, R. A. Systematic and integrative analysis of large gene lists using DAVID Bioinformatics resources. Nature Protoc. 4(1), 44\u201357 (2009).","journal-title":"Nature Protoc."},{"issue":"4","key":"38314_CR55","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1006\/meth.2001.1262","volume":"25","author":"KJ Livak","year":"2001","unstructured":"Livak, K. J. & Schmittgen, T. D. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods. 25(4), 402\u20138 (2001).","journal-title":"Methods."},{"issue":"10","key":"38314_CR56","doi-asserted-by":"publisher","first-page":"e47","DOI":"10.1093\/nar\/30.10.e47","volume":"30","author":"RM Cawthon","year":"2002","unstructured":"Cawthon, R. M. Telomere measurement by quantitative PCR. Nucleic Acids Research. 30(10), e47\u2013e (2002).","journal-title":"Nucleic Acids Research."},{"issue":"3","key":"38314_CR57","doi-asserted-by":"publisher","first-page":"e21","DOI":"10.1093\/nar\/gkn1027","volume":"37","author":"RM Cawthon","year":"2009","unstructured":"Cawthon, R. M. Telomere length measurement by a novel monochrome multiplex quantitative PCR method. Nucleic Acids Research. 37(3), e21\u2013e (2009).","journal-title":"Nucleic Acids Research."},{"issue":"2","key":"38314_CR58","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/j.exphem.2009.11.009","volume":"38","author":"K Todoerti","year":"2010","unstructured":"Todoerti, K. et al. Distinct transcriptional profiles characterize bone microenvironment mesenchymal cells rather than osteoblasts in relationship with multiple myeloma bone disease. Exp. Hematol. 38(2), 141\u201353 (2010).","journal-title":"Exp. Hematol."},{"key":"38314_CR59","doi-asserted-by":"publisher","first-page":"80","DOI":"10.3389\/fendo.2017.00080","volume":"8","author":"HJ Knowles","year":"2017","unstructured":"Knowles, H. J. Multiple roles of angiopoietin-like 4 in osteolytic disease. Frontiers in Endocrinology. 8, 80 (2017).","journal-title":"Frontiers in Endocrinology."},{"key":"38314_CR60","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/j.bone.2016.08.006","volume":"93","author":"J Dotterweich","year":"2016","unstructured":"Dotterweich, J. et al. Contact of myeloma cells induces a characteristic transcriptome signature in skeletal precursor cells -Implications for myeloma bone disease. Bone. 93, 155\u201366 (2016).","journal-title":"Bone."},{"issue":"8","key":"38314_CR61","doi-asserted-by":"publisher","first-page":"2291","DOI":"10.1002\/jbm.a.36095","volume":"105","author":"LB Hang Pham","year":"2017","unstructured":"Hang Pham, L. B. et al. Investigating the effect of fibulin-1 on the differentiation of human nasal inferior turbinate-derived mesenchymal stem cells into osteoblasts. J. Biomed. Mater Res. A. 105(8), 2291\u20132298 (2017).","journal-title":"J. Biomed. Mater Res. A."},{"key":"38314_CR62","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/j.bone.2014.07.038","volume":"69","author":"MA Cooley","year":"2014","unstructured":"Cooley, M. A. et al. Fibulin-1 is required for bone formation and Bmp-2-mediated induction of Osterix. Bone. 69, 30\u20138 (2014).","journal-title":"Bone."},{"issue":"5","key":"38314_CR63","doi-asserted-by":"publisher","first-page":"e2213","DOI":"10.1371\/journal.pone.0002213","volume":"3","author":"W Wagner","year":"2008","unstructured":"Wagner, W. et al. Replicative senescence of mesenchymal stem cells: a continuous and organized process. PLoS One. 3(5), e2213 (2008).","journal-title":"PLoS One."},{"key":"38314_CR64","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-015-1078-3","volume":"15","author":"R Berenstein","year":"2015","unstructured":"Berenstein, R. et al. Multiple myeloma cells alter the senescence phenotype of bone marrow mesenchymal stromal cells under participation of the DLK1-DIO3 genomic region. BMC Cancer. 15, 68 (2015).","journal-title":"BMC Cancer."},{"issue":"5","key":"38314_CR65","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1111\/j.1365-2141.2007.06705.x","volume":"138","author":"G Pratt","year":"2007","unstructured":"Pratt, G., Goodyear, O. & Moss, P. Immunodeficiency and immunotherapy in multiple myeloma. Br. J. Haematol. 138(5), 563\u201379 (2007).","journal-title":"Br. J. Haematol."},{"issue":"11","key":"38314_CR66","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1007\/s00262-014-1589-9","volume":"63","author":"WMT Braga","year":"2014","unstructured":"Braga, W. M. T. et al. FOXP3 and CTLA4 overexpression in multiple myeloma bone marrow as a sign of accumulation of CD4(+) T regulatory cells. Cancer Immunology, Immunotherapy. 63(11), 1189\u201397 (2014).","journal-title":"Cancer Immunology, Immunotherapy."},{"issue":"1","key":"38314_CR67","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1182\/blood.V90.1.340","volume":"90","author":"NE Kay","year":"1997","unstructured":"Kay, N. E. et al. Circulating blood B cells in multiple myeloma: analysis and relationship to circulating clonal cells and clinical parameters in a cohort of patients entered on the Eastern Cooperative Oncology Group phase III E9486 clinical trial. Blood. 90(1), 340\u20135 (1997).","journal-title":"Blood."},{"issue":"3","key":"38314_CR68","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1046\/j.1365-2141.1998.00609.x","volume":"100","author":"NE Kay","year":"1998","unstructured":"Kay, N. E. et al. T-helper phenotypes in the blood of myeloma patients on ECOG phase III trials E9486\/E3A93. Br. J. Haematol. 100(3), 459\u201363 (1998).","journal-title":"Br. J. Haematol."},{"issue":"1","key":"38314_CR69","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1182\/blood.V98.1.23","volume":"98","author":"NE Kay","year":"2001","unstructured":"Kay, N. E. et al. Blood levels of immune cells predict survival in myeloma patients: results of an Eastern Cooperative Oncology Group phase 3 trial for newly diagnosed multiple myeloma patients. Blood. 98(1), 23\u20138 (2001).","journal-title":"Blood."},{"key":"38314_CR70","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1186\/s13045-016-0345-3","volume":"9","author":"C Zelle-Rieser","year":"2016","unstructured":"Zelle-Rieser, C. et al. T cells in multiple myeloma display features of exhaustion and senescence at the tumor site. Journal of Hematology & Oncology. 9, 116 (2016).","journal-title":"Journal of Hematology & Oncology."},{"issue":"10","key":"38314_CR71","doi-asserted-by":"publisher","first-page":"2992","DOI":"10.1182\/blood.V98.10.2992","volume":"98","author":"RD Brown","year":"2001","unstructured":"Brown, R. D. et al. Dendritic cells from patients with myeloma are numerically normal but functionally defective as they fail to up-regulate CD80 (B7-1) expression after huCD40LT stimulation because of inhibition by transforming growth factor-beta1 and interleukin-10. Blood. 98(10), 2992\u20138 (2001).","journal-title":"Blood."},{"issue":"1","key":"38314_CR72","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1111\/j.1365-2249.2006.03037.x","volume":"144","author":"MK Brimnes","year":"2006","unstructured":"Brimnes, M. K., Svane, I. M. & Johnsen, H. E. Impaired functionality and phenotypic profile of dendritic cells from patients with multiple myeloma. Clin. Exp. Immunol. 144(1), 76\u201384 (2006).","journal-title":"Clin. Exp. Immunol."},{"issue":"1","key":"38314_CR73","doi-asserted-by":"publisher","first-page":"79","DOI":"10.3324\/haematol.2012.067272","volume":"98","author":"RJ Pessoa de Magalh\u00e3es","year":"2013","unstructured":"Pessoa de Magalh\u00e3es, R. J. et al. Analysis of the immune system of multiple myeloma patients achieving long-term disease control by multidimensional flow cytometry. Haematologica. 98(1), 79\u201386 (2013).","journal-title":"Haematologica."},{"issue":"7","key":"38314_CR74","doi-asserted-by":"publisher","first-page":"858","DOI":"10.1080\/15384101.2018.1442624","volume":"17","author":"D Chen","year":"2018","unstructured":"Chen, D. et al. Bone marrow-derived mesenchymal stem cells promote cell proliferation of multiple myeloma through inhibiting T cell immune responses via PD-1\/PD-L1 pathway. Cell Cycle. 17(7), 858\u201387 (2018).","journal-title":"Cell Cycle."},{"key":"38314_CR75","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1111\/j.1749-6632.2009.05347.x","volume":"1192","author":"E Hesse","year":"2010","unstructured":"Hesse, E. et al. Zinc finger protein 521, a new player in bone formation. Ann N Y Acad Sci. 1192, 32\u20137 (2010).","journal-title":"Ann N Y Acad Sci."},{"key":"38314_CR76","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1038\/bonekey.2012.183","volume":"1","author":"T Negishi-Koga","year":"2012","unstructured":"Negishi-Koga, T. & Takayanagi, H. Bone cell communication factors and Semaphorins. Bonekey Rep. 1, 183 (2012).","journal-title":"Bonekey Rep."},{"issue":"5","key":"38314_CR77","doi-asserted-by":"publisher","first-page":"1661","DOI":"10.1182\/blood-2006-04-014563","volume":"108","author":"A Vacca","year":"2006","unstructured":"Vacca, A. et al. Loss of inhibitory semaphorin 3A (SEMA3A) autocrine loops in bone marrow endothelial cells of patients with multiple myeloma. Blood. 108(5), 1661\u20137 (2006).","journal-title":"Blood."},{"issue":"6","key":"38314_CR78","doi-asserted-by":"publisher","first-page":"2736","DOI":"10.1172\/JCI73072","volume":"124","author":"LD Mesner","year":"2014","unstructured":"Mesner, L. D. et al. Bicc1 is a genetic determinant of osteoblastogenesis and bone mineral density. J. Clin. Invest. 124(6), 2736\u201349 (2014).","journal-title":"J. Clin. Invest."},{"key":"38314_CR79","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1093\/bioinformatics\/btp073","volume":"25","author":"JP de Magalh\u00e3es","year":"2009","unstructured":"de Magalh\u00e3es, J. P., Curado, J. & Church, G. M. Meta-analysis of age-related gene expression profiles identifies common signatures of aging. Bioinformatics. 25, 875\u201381 (2009).","journal-title":"Bioinformatics."},{"issue":"7396","key":"38314_CR80","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1038\/nature11000","volume":"485","author":"M Hayashi","year":"2012","unstructured":"Hayashi, M. et al. Osteoprotection by semaphorin 3A. Nature. 485(7396), 69\u201374 (2012).","journal-title":"Nature."},{"issue":"9","key":"38314_CR81","doi-asserted-by":"publisher","first-page":"2044","DOI":"10.1016\/j.celrep.2017.08.020","volume":"20","author":"J Zhou","year":"2017","unstructured":"Zhou, J. et al. NEIL3 Repairs Telomere Damage during S Phase to Secure Chromosome Segregation at Mitosis. Cell Rep. 20(9), 2044\u201356 (2017).","journal-title":"Cell Rep."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-018-38314-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-018-38314-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-018-38314-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,17]],"date-time":"2022-12-17T05:21:07Z","timestamp":1671254467000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-018-38314-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1,31]]},"references-count":81,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2019,12]]}},"alternative-id":["38314"],"URL":"https:\/\/doi.org\/10.1038\/s41598-018-38314-8","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,1,31]]},"assertion":[{"value":"23 August 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 December 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 January 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}],"article-number":"1056"}}